Objective The objective of this study was to evaluate the clinical utility of gallium-68 [68Ga] prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) with rising prostate-specific antigen (PSA) levels in prostate cancer diagnosis. This evidence concerns the gene FOLH1 and Familial prostate cancer.